Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Gregory Pearl

Vascular Surgery Dallas, TX Medical Doctor

NPI 1720041783 CMS profile 33048

621 N Hall St, Ste 100, Dallas, TX 75226

Open in the dashboard

General payments

$2,294,738

285 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Gregory Pearl of Dallas, TX is reported in the CMS Open Payments database as having received $2,294,738 across 285 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,290,128 55
2024 General $821 34
2023 General $1,072 53
2022 General $964 41
2021 General $567 29
2020 General $397 17
2019 General $789 56

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Gregory Pearl
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Gregory Pearl were reported at $2,290,128. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Gregory Pearl Vascular Surgery median Middle half National median
2019 $789 $796 $226–$2,363 $163
2020 $397 $348 $118–$1,110 $114
2021 $567 $471 $158–$1,421 $132
2022 $964 $725 $222–$2,183 $149
2023 $1,072 $836 $257–$2,440 $160
2024 $821 $909 $252–$2,619 $164
2025 $2,290,128 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Tendyne Holdings, Inc. $2,288,842 1 payment
  2. Janssen Pharmaceuticals, Inc $620 41 payments
  3. AxoGen $523 24 payments
  4. E.R. Squibb & Sons, L.L.C. $423 30 payments
  5. Pfizer Inc. $313 21 payments
  6. AstraZeneca Pharmaceuticals LP $307 16 payments
  7. Imperative Care, INc $265 9 payments
  8. Endologix, Inc. $226 3 payments
  9. W. L. Gore & Associates, Inc. $196 8 payments
  10. Tactile Systems Technology Inc $191 11 payments
  11. Other $2,833 121 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Acquisitions $2,288,842 1 payment
  2. Food and Beverage $5,896 284 payments
Products named General payments · program years 2019–2025
  1. XARELTO $620 41 payments
  2. ELIQUIS Cardiovascular $379 28 payments
  3. ELIQUIS Cardiovascular;Metabolic Disease $313 21 payments
  4. SYMPHONY CATHETER $265 9 payments
  5. Alto Abdominal Stent Graft System $192 2 payments
  6. Entre Plus $191 11 payments
  7. Flexitouch Plus $191 11 payments
  8. ENROUTE Transcarotid Stent $158 6 payments
  9. ENROUTE Transcarotid Neuroprotection System $158 6 payments
  10. IN.PACT Admiral $149 1 payment
  11. Other $4,252 189 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

22

Median for Vascular Surgery: 122

Drug cost

$122

Median for Vascular Surgery: $14,135

Branded share of claims

0%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycodone Hcl Generic 22 $122

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 19 billing codes

Paid by Medicare

$15,138

Medicare's payments for the services billed

Medicare patients

32

Average age 63

Services billed

78

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 69%
High blood pressure 53%
Depression 41%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ELIQUIS
  • E.R. Squibb & Sons, L.L.C. $33
$33 — —
XARELTO
  • Janssen Pharmaceuticals, Inc $19
$19 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

285 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular Surgery in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record